New targeted pill shows promise for rare bile duct cancer in small trial
NCT ID NCT06081829
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a daily pill called ivosidenib in 12 Japanese patients with advanced bile duct cancer that has an IDH1 mutation and has already been treated with other therapies. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants take the pill once a day and are monitored with scans, blood tests, and checkups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivosidenib (a targeted cancer pill)
What this could lead to
If successful, this could provide a new oral treatment option for people with a specific genetic subtype of bile duct cancer that has stopped responding to other therapies.
What could go wrong
This is a small, early-phase study with only 12 participants, so results may not apply broadly. The drug may not control the cancer for long or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hokkaido University Hospital (JPN-006)
Sapporo, 060-8648, Japan
-
Kanagawa Cancer Center (JPN-003)
Yokohama, 241-8515, Japan
-
Kumamoto University Hospital (JPN-004)
Kumamoto, 860-8556, Japan
-
National Cancer Center Hospital (JPN-001)
Tokyo, Japan
-
National Cancer Center Hospital East (JPN-002)
Kashiwa, 277-8577, Japan
-
National Hospital Organization Shikoku Cancer Center (JPN-007)
Matsuyama, 791-0280, Japan
-
Osaka International Cancer Institute (JPN-005)
Osaka, 541-8567, Japan